Argos Therapeutics Competitors

Argos Therapeutics (OTCMKTS:ARGSQ) and Inspyr Therapeutics (OTCMKTS:NSPX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Argos Therapeutics and Inspyr Therapeutics, as provided by MarketBeat.

Volatility & Risk

Argos Therapeutics has a beta of 2.47, meaning that its stock price is 147% more volatile than the S&P 500. Comparatively, Inspyr Therapeutics has a beta of -16.55, meaning that its stock price is 1,755% less volatile than the S&P 500.

Valuation & Earnings

This table compares Argos Therapeutics and Inspyr Therapeutics' gross revenue, earnings per share and valuation.

Inspyr Therapeutics has lower revenue, but higher earnings than Argos Therapeutics.

Profitability

This table compares Argos Therapeutics and Inspyr Therapeutics' net margins, return on equity and return on assets.

Summary

Argos Therapeutics beats Inspyr Therapeutics on 3 of the 4 factors compared between the two stocks.

VIVUS (OTCMKTS:VVUSQ) and Argos Therapeutics (OTCMKTS:ARGSQ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and price targets for VIVUS and Argos Therapeutics, as reported by MarketBeat.com.

Risk & Volatility

VIVUS has a beta of -3.25, suggesting that its share price is 425% less volatile than the S&P 500. Comparatively, Argos Therapeutics has a beta of 2.47, suggesting that its share price is 147% more volatile than the S&P 500.

Valuation and Earnings

This table compares VIVUS and Argos Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

VIVUS has higher revenue and earnings than Argos Therapeutics.

Profitability

This table compares VIVUS and Argos Therapeutics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

7.3% of VIVUS shares are owned by institutional investors. 12.0% of VIVUS shares are owned by insiders. Comparatively, 28.2% of Argos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Argos Therapeutics beats VIVUS on 5 of the 8 factors compared between the two stocks.

ImmunoCellular Therapeutics (OTCMKTS:IMUCD) and Argos Therapeutics (OTCMKTS:ARGSQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends.

Profitability

This table compares ImmunoCellular Therapeutics and Argos Therapeutics' net margins, return on equity and return on assets.

Risk and Volatility

ImmunoCellular Therapeutics has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500. Comparatively, Argos Therapeutics has a beta of 2.47, meaning that its share price is 147% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ImmunoCellular Therapeutics and Argos Therapeutics, as reported by MarketBeat.

Valuation & Earnings

This table compares ImmunoCellular Therapeutics and Argos Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

ImmunoCellular Therapeutics has higher earnings, but lower revenue than Argos Therapeutics.

Summary

Argos Therapeutics beats ImmunoCellular Therapeutics on 2 of the 3 factors compared between the two stocks.

Capstone Therapeutics (OTCMKTS:CAPS) and Argos Therapeutics (OTCMKTS:ARGSQ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.

Volatility & Risk

Capstone Therapeutics has a beta of 176.15, suggesting that its stock price is 17,515% more volatile than the S&P 500. Comparatively, Argos Therapeutics has a beta of 2.47, suggesting that its stock price is 147% more volatile than the S&P 500.

Profitability

This table compares Capstone Therapeutics and Argos Therapeutics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Capstone Therapeutics and Argos Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Capstone Therapeutics has higher revenue and earnings than Argos Therapeutics.

Analyst Ratings

This is a summary of recent ratings for Capstone Therapeutics and Argos Therapeutics, as reported by MarketBeat.

Insider & Institutional Ownership

2.6% of Capstone Therapeutics shares are owned by institutional investors. 42.8% of Capstone Therapeutics shares are owned by insiders. Comparatively, 28.2% of Argos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Capstone Therapeutics beats Argos Therapeutics on 6 of the 6 factors compared between the two stocks.

Argos Therapeutics (OTCMKTS:ARGSQ) and W World (OTCMKTS:WWHC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Profitability

This table compares Argos Therapeutics and W World's net margins, return on equity and return on assets.

Risk & Volatility

Argos Therapeutics has a beta of 2.47, meaning that its share price is 147% more volatile than the S&P 500. Comparatively, W World has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500.

Valuation & Earnings

This table compares Argos Therapeutics and W World's gross revenue, earnings per share and valuation.

W World has lower revenue, but higher earnings than Argos Therapeutics.

Analyst Ratings

This is a summary of current recommendations and price targets for Argos Therapeutics and W World, as provided by MarketBeat.

Institutional & Insider Ownership

0.1% of W World shares are held by institutional investors. 28.2% of Argos Therapeutics shares are held by company insiders. Comparatively, 61.1% of W World shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Argos Therapeutics (OTCMKTS:ARGSQ) and ImmunoCellular Therapeutics (OTCMKTS:IMUC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Profitability

This table compares Argos Therapeutics and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Volatility & Risk

Argos Therapeutics has a beta of 2.47, meaning that its stock price is 147% more volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.

Valuation & Earnings

This table compares Argos Therapeutics and ImmunoCellular Therapeutics' gross revenue, earnings per share and valuation.

ImmunoCellular Therapeutics has lower revenue, but higher earnings than Argos Therapeutics.

Analyst Ratings

This is a summary of current recommendations and price targets for Argos Therapeutics and ImmunoCellular Therapeutics, as provided by MarketBeat.

Summary

Argos Therapeutics beats ImmunoCellular Therapeutics on 2 of the 2 factors compared between the two stocks.